Vertex Pharmaceuticals | VRTX - أصول متداولة





أصول متداولة تغيير تاريخ
AbbVie USD 33.67B 140M 2026-06
Acadia Pharmaceuticals USD 1.22B 128.53M 2026-06
Agios Pharmaceuticals USD 717.67M 117.18M 2026-06
Alnylam Pharmaceuticals USD 5.11B 492.49M 2026-09
Amgen USD 34.96B 3.49B 2026-06
Arrowhead Research USD 1.67B 168.34M 2026-06
Biogen USD 7.58B 278.7M 2026-09
BioMarin Pharmaceutical USD 3.92B 50.99M 2026-09
Bristol-Myers Squibb USD 29.77B 1.19B 2026-09
Gilead Sciences USD 16.55B 4.02B 2026-09
Incyte USD 5.52B 505.2M 2026-09
Insmed USD 1.71B 72.59M 2026-09
Ionis Pharmaceuticals USD 2.49B 446.73M 2026-06
J&J USD 56.35B 3.42B 2026-09
Merck USD 36.68B 1.66B 2026-06
Moderna USD 5.82B 45M 2026-06
Neurocrine Biosciences USD 2.01B 370.7M 2026-09
Novartis USD 28.75B 1.4B 2026-09
Pfizer USD 41.36B 1.46B 2026-06
PTC Therapeutics USD 2.54B 79.58M 2026-09
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 20.8B 2.35B 2026-09
Roche Holding CHF 35.44B 3.29B 2026-06
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 33.21B 1.68B 2026-09
Sarepta Therapeutics USD 2.22B 86.05M 2026-06
Ultragenyx Pharmaceutical USD 606M 51M 2026-06
United Therapeutics USD 3.48B 611.7M 2026-06
Vertex Pharmaceuticals USD 11.69B 857.4M 2026-09